Universitätsklinikum Tübingen

Hospital


Location: Tübingen, Germany (DE) DE

ISNI: 0000000101968249

ROR: https://ror.org/00pjgxh97

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Factors Predicting Discordance in HER2 Phenotype between Primary Tumor and Circulating Tumor Cells in Women with Metastatic Breast Cancer (2016) Janni W, Schramm A, Friedl TWP, Schochter E, Huober J, Rack B, Alunni-Fabbroni M, et al. Conference contribution Effects of DMARD Tapering on Treatment Costs and Work Productivity in Rheumatoid Arthritis Patients- an Analysis from the Prospective Randomized Controlled Retro- Study (2016) Hagen M, Figueiredo CP, Cobra JF, Haschka J, Reiser M, Englbrecht M, Hueber A, et al. Conference contribution ANTI-MODIFIED PROTEIN ANTIBODY RESPONSE PATTERN INFLUENCES THE RISK FOR DISEASE RELAPSE IN RHEUMATOID ARTHRITIS PATIENTS TAPERING DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (2016) Figueiredo C, Bang H, Cobra JF, Englbrecht M, Hueber AJ, Haschka J, Manger B, et al. Conference contribution The DETECT Study Concept - Metastatic breast cancer and circulating tumor cells (2016) Schramm A, Friedl T, Rack B, Trapp E, Fasching P, Taran FA, Hartkopf A, et al. Conference contribution Outcome on 560 metastatic melanoma (MM) patients treated with pembrolizumab during the German Expanded Access Program (EAP) (2016) Hassel J, Forschner A, Bluhm L, Heinzerling L, Zimmer L, Utikal J, Kaehler K, et al. Conference contribution EFFECTS OF DMARD TAPERING ON TREATMENT COSTS IN RHEUMATOID ARTHRITIS PATIENTS-AN ANALYSIS FROM THE PROSPECTIVE RANDOMIZED CONTROLLED RETROSTUDY (2016) Hagen M, Figueiredo C, Cobra JF, Reiser M, Haschka J, Englbrecht M, Hueber A, et al. Conference contribution Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab (2016) Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, Simeone E, et al. Journal article Oncological heath care networks. The triangle formed by research, quality, and competition (2016) Schrauder MG, Bamberg M, Beckmann M Journal article Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial (2016) Eigentler TK, Gutzmer R, Hauschild A, Heinzerling L, Schadendorf D, Nashan D, Hoelzle E, et al. Journal article Health-related Quality of Life in Metastatic and Adjuvant Breast Cancer Patients (2016) Wallwiener M, Simoes E, Sokolov AN, Brucker SY, Fasching P, Graf J Journal article